Myeloma

A Phase 1/2 clinical trial testing an experimental T-cell therapy for the first time in human patients will begin in the coming weeks after receiving…

Scientists have developed a new test that shortens the time it takes to assess the success of bone marrow transplants — to a few days…

To raise awareness of multiple myeloma and funding for research, 18 patients, caregivers, and healthcare professionals have embarked on a challenging ascent to Mount Everest…

Immune factors that drive donor T-cells to cause graft-versus-host disease (GVHD) have been found by researchers whose discovery may offer new opportunities for therapeutic…

Treatment of bone lesions in multiple myeloma patients with Amgen’s Xgeva (denosumab) may be expanded to European patients following a positive opinion from…

Newly diagnosed multiple myeloma patients unable to undergo stem cell transplants lived significantly longer without their disease progressing when given continuous treatment with…

As UT Southwestern and Celgene Corporation join efforts to launch a new clinical trial to evaluate a chimeric antigen receptor T-cell therapy,…

The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private organization funding collaborative translational science, recently launched the Adelson Program in…

A combination treatment including Pomalyst (pomalidomide) significantly extended the time until disease progression or death in patients with relapsed or refractory multiple myeloma who were…

PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for…